Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Amgen sheds around 40 staffers amid continuing struggles
(2d)
Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effects
(2d)
Merck stages expanded access to monthly HIV PrEP pill ahead of approval
(2d)
BioPharma Dive
Sanofi halts development of troubled immune drug in eczema
(2d)
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
(2d)
Scribe secures $129M in a rare gene editing IPO
(3d)
Endpoints News
Anthropic’s life science plans; Novartis CEO on China deals; and more
(1d)
Amgen shares new Tavneos analysis in effort to resolve FDA dispute
(2d)
Ipsen’s Bylvay fails key trial in children with rare liver disease
(2d)
BioSpace
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
(2d)
Amgen deploys patients to defend troubled Tavneos in FDA hearing request
(2d)
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
(2d)
STAT News
I led the FDA’s food safety and nutrition center. Here’s what people are missing about the cyclospora outbreak
(2d)
FDA advisory panel narrowly rejects compounding of one peptide, back another
(2d)
There are already more U.S. measles cases this year than in all of 2025
(2d)
BioPharma Trend
Seven HealthTech Trends In Europe To Watch
(1mo)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(1mo)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(2mo)
Drug Channels
Direct-to-Patient: Transforming the Manufacturer Access Model
(2d)
2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges
(5d)
2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges
(5d)
European Biotechnology Magazine
CHMP backs Minoryx’s rare disease drug two years after rejection
(2d)
Sanofi drops eczema drug from $1.1B Kymab deal
(2d)
Iceland-based Synaptiq launches with Nobias’ rare disease drug
(2d)
Drug Hunter
zidebactam
(2d)
centanafadine
(3d)
thalidomide
(4d)
Labiotech.EU
Munich’s biotech hub: Inside one of Europe’s leading life sciences ecosystems
(2d)
This nonprofit is building the ecosystem to cure epidermolysis bullosa
(2d)
Is an HIV cure possible? The future of HIV therapy
(4d)
Bio IT World
The Most Expensive AI Mistake in Biotech Isn’t a Hallucination, It’s a Process Failure
(2d)
In Vivo CRISPR Therapy is One Step Closer to the Clinic
(3d)
Different Teams, Same Problem
(4d)
GEN News
Colorectal Cancer Targeted with Mass-Produced iPSC-Derived Allogeneic T Cells
(2d)
Oral Antiviral Blocks Measles-Like Virus Transmission in Ferrets
(2d)
Single-Cell Atlas Simultaneously Maps 3D Genome Architecture and DNA Methylation
(2d)
Cure Today
Why I Chose a Treatment Break After Years of Living With Stage 4 Ovarian Cancer
(1d)
When the Scan Is Over but the Waiting Begins: Living With Lymphoma Scanxiety
(2d)
RASolute 302 and the Future of Pancreatic Cancer Treatment: Paul Oberstein, MD, on the KRAS Breakthrough
(2d)
Contract Pharma
Asymchem Carbapenem API Site in China Successfully Completes First FDA Inspection
(2d)
Federal Equipment Announces Turnkey Sale of Denison Pharmaceuticals Facility
(2d)
Neurocrine Biosciences Names New Senior Vice Presidents
(2d)
Pharma Times
GSK wins US approval for ROS1 lung cancer therapy
(3d)
Lundbeck secures FDA Fast Track for narcolepsy drug
(3d)
R1 Therapeutics begins global phase 2b trial of AP306 for hyperphosphatemia
(4d)
Medcity News
Candid Health Snags $120M for AI RCM Platform
(9h)
Why Value-Based Care Only Works If You’ve Tamed Costs
(10h)
Medicine Understands Trauma’s Impact, But Rarely Asks About It
(10h)
Chemical & Engineering News
Rudy Marcus, developer of electron transfer theory, dies at 102
(2d)
ACS continues 150th celebration at EuChemS
(2d)
Policy Watch: DHS puts new limit on international student stays in the US
(2d)
The Pharma Letter
The week in pharma: action, reaction and insight – week to July 24, 2026
(13h)
Kaveri Therapeutics
(1d)
India’s pharma M&A market hits four-year high on blockbuster deals
(1d)
Targeted Oncology
MCED Testing: Preparing for the Next Era of Cancer Risk Assessment
(8h)
Biomarkers Beyond High TMB or MMR-D May Be Needed for ICIs in Sarcomas
(11h)
Community Clinical Trials and the Lung Cancer Pipeline
(13h)
MedWatch
Novo Nordisk's tablet sales continue to rise following a new subsidy scheme in the US
(2d)
Sanofi discontinues eczema treatment following strategic review
(2d)
Demant grew market share among US veterans in June
(2d)
In The Pipeline
Clinical Failure Rates Over the Decades: Yikes
(2d)
The Assault On Science Funding Continues
(3d)
Thoughts on the "Netflix Analogy"
(4d)
Pharmaphorum
Ipsen' Bylvay fluffs its lines in biliary atresia trial
(2d)
Sanofi gives up on amlitelimab in atopic dermatitis
(2d)
Re-rostered FDA committee backs peptide compounding
(2d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(1mo)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(1mo)
Webinar: Learn how to accelerate the early stages of drug discovery
(1mo)
HIT Consultant
Medidata Launches Medidata Plus AI Layer to Standardize Clinical Trial Data and Workflows
(2d)
Wellumio Closes $9.75M to Commercialize Axana Portable Brain Imaging Device
(2d)
Cigna Healthcare Expands AI-Enabled Care Management to Reach 20% More Customers
(2d)
Insights: Pink Sheet
Peptide Industry Reaps Six Wins From RFK Jr.-Remade FDA Panel
(2d)
New ADVOCATE Analysis Backs Tavneos Efficacy, Amgen Tells US FDA In Withdrawal Dispute
(2d)
J&J’s Icotyde Nears EU Finish Line As First Oral IL-23 Receptor Drug For Plaque Psoriasis
(2d)
BioXconomy
SEC's semiannual reporting proposal debate continues
(2d)
Emerging IP trends for large molecules, CAR-T therapies, and biosimilars
(2d)
Royalty Pharma takes $425m interest in AZ’s cardiovascular drug
(2d)
BioCentury
Song among trio of new partners at Venrock
(2d)
Hub 101: Taiwan biotech looks to level up
(2d)
EMA’s CHMP backs two orphan drugs, rebuffs FDA-approved NPC therapy
(2d)
SCRIP
Novo Nordisk Doubles Down On Efforts To Halt Lilly Tirzepatide Ads
(2d)
Merck Signs License Agreements For Monthly PrEP Drug Alimatravir In Developing Countries
(2d)
SMID Caps In The Buyer’s Seat
(2d)